Millennium Pharmaceuticals Limited

Other

Millenium Pharmaceuticals, Inc.

Csanad M Varga

Vaithianathan Palaniappan

Nobel T Truong

Phuong Nguyen

Raymond D Skwierczynski

Michael J Kaufman

Eric L Elliott

Quentin J McCubbin

Debra L Mazaik

Abu J Ferdous

Peter Zawaneh

Irving H Fox

Catherine Scholz

Willow Diluzio

Jason W Brown

Willow Ruth Diluzio

Sonja A Komar-Lay

Sonja A Komar

Maria Rosario

Peter N Zawaneh

Phoung M Nguyen

Quentin J Mccubbin

Helen Jenkins

Catherine Rose Scholz

Sonja A Komar Lay

Phuong M Nguyen

Erica Helen Jenkins

Antibody formulations are described comprising a mixture of an anti-&#x3b1;4&#x3b2;7 antibody, an antioxidant or chelator, and at least one free amino acid. The disclosed formulations may have improved stability, reduced aggregate formation, or both. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-&#x3b1;4&#x3b2;7 antibody in vivo.

Formulation for anti-&#x3b1;4&#x3b2;7 antibody

The present invention provides novel compounds useful as proteasome inhibitors. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various diseases.

Boronate ester compounds and pharmaceutical compositions thereof

Antibody formulations are described comprising a mixture of a non-reducing sugar, an anti-&#x3b1;4&#x3b2;7 antibody and at least one amino acid. The disclosed formulations have improved stability, reduced aggregate formation, and may retard degradation of the anti-&#x3b1;4&#x3b2;7 antibody therein or exhibit any combinations thereof. The present invention further provides a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-&#x3b1;4&#x3b2;7 antibody in vivo.

Growing community of inventors

Newton, MA, United States of America

Csanad M Varga